Dr. Pierre BOHN
Fonction : Pharmacien - Professeur Associé des Universités
Groupe : Quantif
Publications associées
- Quantitative MRI to Characterize Hypoxic Tumors in Comparison to FMISO PET/CT for Radiotherapy in Oropharynx Cancers.
Cancers (Basel) · 2023 - Advances in PET and MRI imaging of tumor hypoxia.
Front Med (Lausanne). · 2023 - First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer.
First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer. · 2021 - Targeting the Urotensin II/UT G Protein-Coupled Receptor to Counteract Angiogenesis and Mesenchymal Hypoxia/Necrosis in Glioblastoma.
Front Cell Dev Biol · 2021 - Angiogenesis imaging study using interim [18F] RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence.
EJNMMI Res · 2021 - Immunotherapy by immune checkpoint inhibitors and nuclear medicine imaging : current ant future applications.
Cancers (Basel) · 2020 - Comparison of hypermetabolic and hypoxic volumes delineated on [18F] FDG an [18F] Fluoromisonidazole PET/CT in non-smal-cell lung cancer patients.
Mol Imaging Biol · 2020 - Development of 111-In-Labelled DOTA urotensin II analogues for targeting the UT receptor overexpressed in solid tumours.
Biomolecules · 2020 - The added value of clinical radiopharmacists in nuclear medicine : the example of flomerular filtration rate assessment in kidney donors.
J Clin Pharm Ther · 2020 - Benefits of positron emission tomography scans for the evaluation of radiotherapy.
Benefits of positron emission tomography scans for the evaluation of radiotherapy. · 2020 - Red cell volume measurement : using technetium as a replacement for chromium.
Nucl Med Commun · 2020 - Discontinuation of Chromium-51 for clinical use : what are the possible alternatives for radiopharmacies and nuclear medicine departments ?
Ann Pharm Fr · 2020 - Radiotherapy boost in patients with hypoxic lesions identified by F-FMISO PET/CT in non small cell lung carcinoma : can we expect a better survival outcome without toxicity ? (RTEP5 study).
EJNMMI · 2019 - Comparison of hypermetabolic and hypoxic volumes delineated on 18FDG an 18Fmisonidazole PET-CT in non-small cell lung cancer patients.
Mol Imaging Biol · 2019 - Real-time molecular optical micro-imaging of EGFR mutations using a fluorescent erlotinib based tracer.
BMC Pulm Med · 2019